GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates
(hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.
- (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.
- In recent years, immunotherapeutic antibody drugs targeting PD-1 and PD-L1 (representing immune checkpoint inhibitors) have revolutionized cancer therapy.
- Linker stability is extremely important in the field of antibody immune agonist conjugates.
- GeneQuntum focuses on the development of differentiated innovation products through in-house research and development and diversified external research and development cooperation.